Eastham James A, Kattan Michael W, Fearn Paul, Fisher Gabrielle, Berney Daniel M, Oliver Tim, Foster Christopher S, Møller Henrik, Reuter Victor, Cuzick Jack, Scardino Peter
Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Eur Urol. 2008 Feb;53(2):347-54. doi: 10.1016/j.eururo.2007.05.015. Epub 2007 May 30.
Men with clinically detected localized prostate cancer treated without curative intent are at risk of complications from local tumor growth. We investigated rates of local progression and need for local therapy among such men.
Men diagnosed with prostate cancer during 1990-1996 were identified from cancer registries throughout the United Kingdom. Inclusion criteria were age < or =76 yr at diagnosis, PSA level < or =100 ng/ml, and, within 6 mo after diagnosis, no radiation therapy, radical prostatectomy, evidence of metastatic disease, or death. Local progression was defined as increase in clinical stage from T1/2 to T3/T4 disease, T3 to T4 disease, and/or need for transurethral resection of the prostate (TURP) to relieve symptoms >6 mo after cancer diagnosis.
The study included 2333 men with median follow-up of 85 mo (range: 6-174). Diagnosis was by TURP in 1255 men (54%), needle biopsy in 1039 (45%), and unspecified in 39 (2%). Only 29% were treated with hormonal therapy within 6 mo of diagnosis. Local progression occurred in 335 men, including 212 undergoing TURP. Factors most predictive of local progression on multivariable analysis were PSA at diagnosis and Gleason score of the diagnostic tissue (detrimental), and early hormonal therapy (protective). We present a nomogram that predicts the likelihood of local progression within 120 mo after diagnosis.
Men with clinically detected localized prostate cancer managed without curative intent have an approximately 15% risk for local progression within 10 yr of diagnosis. Among those with progression, the need for treatment is common, even among men diagnosed by TURP. When counseling men who are candidates for management without curative intent, the likelihood of symptoms from local progression must be considered.
临床诊断为局限性前列腺癌但未接受根治性治疗的男性存在局部肿瘤生长导致并发症的风险。我们调查了这类男性的局部进展率以及局部治疗需求。
从英国各地的癌症登记处识别出1990 - 1996年期间诊断为前列腺癌的男性。纳入标准为诊断时年龄≤76岁,前列腺特异性抗原(PSA)水平≤100 ng/ml,且在诊断后6个月内未接受放射治疗、根治性前列腺切除术、无转移性疾病证据或死亡。局部进展定义为临床分期从T1/2期进展至T3/T4期、T3期进展至T4期,和/或在癌症诊断后6个月以上需要经尿道前列腺切除术(TURP)以缓解症状。
该研究纳入了2333名男性,中位随访时间为85个月(范围:6 - 174个月)。1255名男性(54%)通过TURP诊断,1039名(45%)通过穿刺活检诊断,39名(2%)诊断方式未明确。仅29%的男性在诊断后6个月内接受了激素治疗。335名男性出现局部进展,其中212名接受了TURP。多变量分析中最能预测局部进展的因素是诊断时的PSA水平、诊断组织的Gleason评分(有害)以及早期激素治疗(有保护作用)。我们给出了一个列线图,可预测诊断后120个月内局部进展的可能性。
临床诊断为局限性前列腺癌但未接受根治性治疗的男性在诊断后10年内发生局部进展的风险约为15%。在出现进展的患者中,即使是通过TURP诊断的男性,治疗需求也很常见。在为不适合根治性治疗的男性提供咨询时,必须考虑局部进展导致症状出现的可能性。